Rheumatology

Among patients with rheumatoid arthritis (RA) in clinical remission, patient-physician discordance when assessing disease activity may be associated with the inability to achieve remission.

A meta-analysis found that a third of patients with rheumatoid arthritis (RA) in a sample had metabolic syndrome, which can double the risk of cardiovascular outcomes in this population.

Results from the CHOICE study suggest that both a 150 mg and 300 mg dose of secukinumab improved symptoms of psoriatic arthritis (PsA) in biologic-naïve patients, with higher response rates for the 300 mg dose.

Patients who received early immunosuppressive therapy for their rheumatoid arthritis (RA)–associated peripheral ulcerative keratitis experienced earlier inflammatory control, fewer recurrences, and better visual outcomes.

The association between higher disease activity risk of cardiovascular (CV) events was strongest during the first 6 months of follow-up, the study found.

Researchers found no association between the use of tofacitinib, tocilizumab, or tumor necrosis factor (TNF) inhibitors and risk of developing Alzheimer disease and related dementia (ADRD) among older patients with rheumatoid arthritis (RA).

Age at symptom presentation was significantly associated with longer symptom duration for children with juvenile idiopathic arthritis (JIA).

Complications were significantly associated with low height, high-dose prednisolone use, and progression of cervical spine lesions in early disease stages of rheumatoid arthritis (RA).

Research shows that disease activity level did not correlate with fat mass percentage among individuals with rheumatoid arthritis (RA).

Patients aged 75 years and older who received a rheumatoid arthritis (RA) diagnosis 2 years ago or less had the highest risk of developing primary open-angle glaucoma (POAG).

Variations between current core outcome sets and how trials are actually measuring self-management among patients with inflammatory arthritis (IA) show the need for further established outcome domains.

The genetically-predicted risk of rheumatoid arthritis (RA) was positively associated with an increased risk of inflammatory bowel disease (IBD) and potentially with its main subtypes, ulcerative colitis and Crohn disease.

Using telemedicine to monitor patients with rheumatoid arthritis (RA) initiating disease-modifying antirheumatic drugs (DMARDs) was highly cost-effective and resulted in similar health outcomes compared with in-person monitoring.

The American College of Rheumatology (ACR) has released updated guidelines on pharmacologic and nonpharmacologic treatments for juvenile idiopathic arthritis.

According to the study, rheumatoid arthritis (RA)-associated autoimmunity was not linked to increased cardiovascular (CV) event risk, suggesting systemic inflammation is likely required for precipitating CV events.

According to data from the Global Burden of Disease study 2019, osteoarthritis (OA) is still globally prevalent and is expected to increase due to rising obesity and the aging of populations.

Defined cut-off scores for patient function and MRI-detected bone erosion may potentially help clinicians and patients with rheumatoid arthritis (RA) in remission decide when to stop treatment.

According to the authors, this is the first study to approach methotrexate intolerance measurement from a patient perspective.

Version 5 of “COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases" includes updated recommendations that differentiate supplemental and booster doses for people with rheumatic and musculoskeletal diseases (RMDs).

Patients with rheumatoid arthritis (RA) who used 3 or more targeted therapies, but not Janus kinase inhibitors, were at greater risk of developing herpes zoster, according to findings from a Korean study.

A patient with medication-induced severe acute generalized exanthematous pustulosis responded to treatment with secukinumab after unsuccessful courses of topical and systemic steroids.

A study found that antibody response against COVID-19 decreased by 2.8 times between months 1 and 6 post vaccination among people with rheumatic and musculoskeletal disease.

Patients with psoriasis who experienced secukinumab secondary failure did not require switching after experiencing significant improvement of daily functioning and quality of life when given a combination rescue therapy.

After analyzing past studies and classification criteria, authors found multiple factors that could be implemented into the current rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) tests for a more specific rheumatoid arthritis (RA) classification.

Women in the study were 3 times more likely to be affected by rheumatoid arthritis (RA) and nearly 4 times more likely to develop hypothyroidism, compared with men.

A study found that frailty reduced the likelihood of comprehensive disease control achievement by patients with rheumatoid arthritis (RA) being treated with a biologic agent.

Neither adalimumab nor secukinumab substantially affected a patient’s immune response to the Pfizer COVID-19 vaccine.

The safety profiles of COVID-19 vaccines in patients with inflammatory rheumatic and musculoskeletal disease (RMD) was comparable with patients with non-inflammatory RMD and the general population, according to a new study.

Investigation into myeloid-related protein 8/14 (MRP8/14) serves as an important next step of translational research to discovering a diagnostic biomarker for systemic juvenile idiopathic arthritis.

Readers were most interested in articles about cost of therapy, drug efficacy, and a unique case related to COVID-19.